DUBLIN, June 23, 2021 /PRNewswire/ -- The "Malignant Ascites Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom. Background: In 2009 the ...

VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints. Background: Malignant ascites (MA) is a symptom of late-stage tumor disease and associated with ...

Oncotarget published "Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites" which reported that the authors aim is to determine the feasibility of cell ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using ...

FORT LAUDERDALE, Fla., Dec. 31, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF), a nonprofit dedicated to raising awareness, funding research, and supporting stomach cancer ...

Becton, Dickinson (NYSE:BDX) has received 510(k) clearance from the FDA for the PeritX Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites. Ascites is a ...

The first bispecific antibody to win regulatory approval is about to make a comeback 10 years after being taken off the market in Europe for commercial reasons. Catumaxomab, then called Removab, and ...